Is Wegovy a peptide? What semaglutide actually is and how it works

You searched 'peptide', here is what that word actually means for Wegovy

Picture someone who has just read about 'peptide injections' online and wonders whether Wegovy belongs in that conversation. It is a fair question. A peptide is simply a molecule built from a sequence of amino acids, shorter than a full protein. Hormones, enzymes and cell-signalling molecules are often peptides. GLP-1 (glucagon-like peptide-1) is one of them. Your gut releases it after a meal, and it tells your brain you have eaten, slows the emptying of your stomach and prompts the pancreas to manage blood sugar.

Semaglutide, the active ingredient in Wegovy, was designed in a laboratory to bind to the same receptor that GLP-1 binds to. By that definition, yes, it is a peptide. But calling it simply a 'peptide injection' understates what it is: a licenced pharmaceutical, regulated by the MHRA, manufactured to tight standards, and dispensed only on prescription. The distinction matters because the term 'peptide' also circulates in wellness circles to describe unregulated compounds of very variable quality. Wegovy is not in that category.

A question our prescribers hear most weeks is whether Wegovy and the various 'peptide therapies' advertised on social media are the same thing. They are not, and if you want to understand how semaglutide peptides sit within that broader landscape, we have set out the distinctions clearly. Wegovy has passed the clinical trials, the regulatory review and the prescribing framework that unregulated peptides have not. You can read more about semaglutide's classification as a peptide in its own right if you want the chemistry in more depth.

Why semaglutide's peptide structure needed engineering to work as a weekly medicine

Natural GLP-1 has a half-life of roughly two minutes in the bloodstream. An enzyme called DPP-4 degrades it almost immediately. That is fine for moment-to-moment regulation after a meal, but useless as a medicine you take once a week.

Novo Nordisk's researchers solved this by attaching a fatty-acid chain to the peptide backbone. That modification lets semaglutide bind loosely to albumin, a protein abundant in blood, which shields it from DPP-4 and the kidneys. The result is a half-life of around one week, long enough for a 2.4 mg weekly injection to maintain a steady effect on appetite, gastric emptying and blood-sugar control. The NHS medicines page for semaglutide describes how the medicine works and what to expect at each stage of treatment.

This engineering also means the molecule cannot simply be swallowed in the way a small-molecule drug can, it would be digested like food. That is why Wegovy has traditionally been an injection. The recently approved oral semaglutide formulation (Wegovy tablets) pairs the peptide with a special absorption enhancer that allows a fraction of the dose to pass through the stomach wall, though the injection remains the established route. If you are curious about how the two delivery routes compare, our page on Wegovy in the UK covers both.

How Wegovy's single-receptor action differs from the dual-agonist approach

Understanding Wegovy's peptide mechanism also helps clarify how it compares to tirzepatide, the active ingredient in Mounjaro. Semaglutide targets one receptor: GLP-1. Tirzepatide is engineered to target two, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Both are peptide-based medicines; they differ in which receptors they activate and with what effect.

In the STEP 1 clinical trial, semaglutide 2.4 mg produced an average weight reduction of around 15% over 68 weeks, a result that, at the time, represented a step change in what medical treatment for obesity could achieve, as reported in the STEP 1 paper published in the New England Journal of Medicine. The SURMOUNT-5 head-to-head trial, published in NEJM in 2025, found tirzepatide produced a greater average reduction than semaglutide 2.4 mg. The newer 7.2 mg semaglutide dose narrows that gap; trials at that strength reported around 20.7% average weight loss over 72 weeks.

Which approach suits a specific person depends on their health history, other medicines, and clinical judgement. That is not something a web page resolves, it is what a proper consultation is for. If you are weighing up the two medicines, our page on weight-loss treatment options gives a grounded overview. For a closer look at semaglutide as a peptide for weight loss, we have covered the evidence separately.

What the 'peptide' label means for how Wegovy is stored and handled

Peptide medicines are generally more delicate than small-molecule drugs. Semaglutide is no exception. Wegovy injection pens are stored in a refrigerator at 2–8°C; once in use, there is a limited window at room temperature, the exact figure is in the Patient Information Leaflet and the SmPC, and that is where it should stay, because the window differs by pen format. Citing a single number here risks being wrong for your specific pen.

Because semaglutide is a biological molecule, manufacturing it to consistent quality is technically demanding. That is part of why counterfeit pens are dangerous, a fake pen might contain a different peptide, no active ingredient at all, or a harmful substitute. The MHRA has seized large quantities of fake weight-loss pens and continues to warn the public about sellers operating without proper authorisation. Any legitimate supply of Wegovy in the UK comes through the licensed supply chain, dispensed by a pharmacy you can verify on the GPhC register.

If you are thinking about starting treatment and want to understand the eligibility criteria and the clinical process, how long Wegovy treatment typically takes is a practical next step to read. When you are ready to speak to a prescriber, starting Wegovy through a regulated UK pharmacy explains the clinical route in plain terms.